


Allen JC, Epstein F. Medulloblastoma and other primary malignant tumors of the CNS. J Neurosurg 1982; 57: 446-452


Bloom HJG. The role of adjuvant chemotherapy in the primary treatment of medulloblastoma and ependymoma. In: Pochedly C (ed.). Controversies in pediatric and adolescent hematology and oncology. CV Mosby, St. Louis, 1989


Dunkel IJ, Finlay JL. High dose chemotherapy with autologous stem cell rescue for patients with medulloblastoma. J Neurooncol 1996; 29: 69-74


Fazekas F. Magnetic resonance signal abnormalities in asymptomatic individuals: their incidence and functional correlates. Eur Neurol 1989; 29 (3):164-168


Frühwald MC, Rickert CH, O’Dorisio MS, et al. Somatostatin receptor subtype 2 is expressed by supratentorial primitive neuroectodermal tumors of childhood and can be targeted for somatostatin receptor imaging. Clin Cancer Res 2004; 10 (9): 2997-3006


Gardner S, Baker D, Belasco J, et al. Phase I dose escalation of temozolomide with thiotapecarboplatin with autologous stem cell rescue (ASCR) in patients with recurrent/refractory central nervous system (CNS) tumors. 11th International Symposium on Pediatric Neuro-Oncology, Boston, 13th-16th June 2004 (abstr)


Groll AH, Walsh TJ. Antifungal Chemotherapy: Recent advances and current perspectives. Swiss Medical Weekly 2002; 132: 303-311


Kühl J. Protokoll HIT 2000, Version vom 01.06.2000


Rutkowski S, Bode U, Deinlein F, et al. Cure of children less than three years with medulloblastoma (M0/M1-stage) by postoperative chemotherapy only: final results of the HIT-SKK'92 Study. 11th International Symposium on Pediatric Neuro-Oncology, Boston, June 13th-16th, 2004 (abstr)
Schäfer H, Müller HH. Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections. Statistics in Medicine 2001; 20: 3741-3751
Segal RA, Goumnerova LC, Kwon YK, et al. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci USA 1994; 91 (26): 12867-12871


Simon R. Optimal two stage designs for phase II clinical trials. Controlled Clinical Trials 1989; 10: 1-10


Zernikow B, Griessinger N, Fengler R. [Practice of pain control in paediatric oncology--recommendations of the quality-monitoring group of the German Society for Paediatric Oncology and Haematology (GPOH)] Schmerz 1999; 13(3): 213-235